Robinul Forte is a drug owned by Casper Pharma Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 24, 2024. Details of Robinul Forte's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7091236 | Method for increasing the bioavailability of glycopyrrolate |
Apr, 2024
(1 year, 6 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Robinul Forte's patents.
Latest Legal Activities on Robinul Forte's Patents
Given below is the list of recent legal activities going on the following patents of Robinul Forte.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Feb, 2018 | US7091236 (Litigated) |
| Change in Power of Attorney (May Include Associate POA)
Critical | 13 Dec, 2012 | US7091236 (Litigated) |
| Email Notification
Critical | 13 Dec, 2012 | US7091236 (Litigated) |
| Correspondence Address Change
Critical | 12 Dec, 2012 | US7091236 (Litigated) |
| Change in Power of Attorney (May Include Associate POA)
Critical | 30 Aug, 2011 | US7091236 (Litigated) |
| Email Notification
Critical | 30 Aug, 2011 | US7091236 (Litigated) |
| Correspondence Address Change
Critical | 26 Aug, 2011 | US7091236 (Litigated) |
| Patent Issue Date Used in PTA Calculation
Critical | 15 Aug, 2006 | US7091236 (Litigated) |
| Recordation of Patent Grant Mailed
Critical | 15 Aug, 2006 | US7091236 (Litigated) |
| Issue Notification Mailed
Critical | 26 Jul, 2006 | US7091236 (Litigated) |
US patents provide insights into the exclusivity only within the United States, but
Robinul Forte is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Robinul Forte's family patents as well as insights into
ongoing legal events
on those patents.
Robinul Forte's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Robinul Forte's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 24, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Robinul Forte Generic API suppliers:
Glycopyrrolate is the generic name for the brand Robinul Forte. 45 different companies have already filed for the generic of Robinul Forte, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Robinul Forte's generic
How can I launch a generic of Robinul Forte before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Robinul Forte's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Robinul Forte's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Robinul Forte -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 1 mg | 14 Aug, 2009 | 1 | 03 Feb, 2014 | 24 Apr, 2024 | Extinguished |
| 2 mg | 12 Oct, 2010 | 1 | 03 Feb, 2014 | 24 Apr, 2024 | Eligible |
Alternative Brands for Robinul Forte
Robinul Forte which is used for treating peptic ulcer as adjunctive therapy., has several other brand drugs in the same treatment category and using the same active ingredient (Glycopyrrolate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Casper Pharma Llc |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Glycopyrrolate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Astrazeneca |
| ||
| Astrazeneca Ab |
| ||
| Azurity |
| ||
| Merz Pharms |
| ||
| Novartis |
| ||
| Sumitomo Pharma Am |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Glycopyrrolate, Robinul Forte's active ingredient. Check the complete list of approved generic manufacturers for Robinul Forte
About Robinul Forte
Robinul Forte is a drug owned by Casper Pharma Llc. It is used for treating peptic ulcer as adjunctive therapy. Robinul Forte uses Glycopyrrolate as an active ingredient. Robinul Forte was launched by Casper Pharma Llc in 1982.
Approval Date:
Robinul Forte was approved by FDA for market use on 01 January, 1982.
Active Ingredient:
Robinul Forte uses Glycopyrrolate as the active ingredient. Check out other Drugs and Companies using Glycopyrrolate ingredient
Treatment:
Robinul Forte is used for treating peptic ulcer as adjunctive therapy.
Dosage:
Robinul Forte is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Prescription | ORAL |